New York, Jan 23, 2026, 08:55 EST — Premarket
- Shares of REVB jumped roughly 2% in premarket trading following an SEC filing that detailed an FDA agreement on its Gemini program targeting acute kidney injury
- The company indicated that a single adaptive Phase 2/3 trial involving about 300 patients might be enough to back a future U.S. approval filing if the data prove favorable
- Traders are focused on when the trial kicks off and how much new capital the micro-cap biotech will require
Revelation Biosciences shares climbed roughly 2% in premarket Friday, adding to a rollercoaster week for the lightly traded biotech. Investors were reacting to the company’s newest regulatory update. The stock last changed hands near $0.85.
This move is crucial as the company aims to consolidate early-stage research into one late-stage trial, which could form the basis of a U.S. marketing application. For micro-cap drug developers, any indication that the Food and Drug Administration agrees on endpoints and trial size can quickly change the risk calculations.
Revelation is zeroing in on acute kidney injury, a sudden decline in kidney function that commonly affects hospitalized patients. No approved drug exists for severe cases, with treatment usually limited to dialysis and supportive care.
In an 8-K filing, the San Diego-based firm revealed it struck a deal with the FDA on an “approval pathway” for Gemini targeting acute kidney injury. Revelation noted that strong data from a single adaptive Phase 2/3 trial involving roughly 300 patients might suffice for a new drug application — the standard submission for U.S. marketing clearance. SEC
The company indicated the trial’s primary measure will be a composite endpoint — combining death and/or dialysis requirements into one outcome. CEO James Rolke described the FDA’s feedback as providing “a clear and expedient path forward,” framing the upcoming phase as focused on execution. SEC
An adaptive design allows developers to tweak elements of a study, like dosing, in response to interim data, all within a predetermined framework. Revelation said it plans to shift from a dose-selection phase directly into phase 3, using the regimen it considers safest.
The stock was volatile Thursday, swinging from about $0.80 up to $1.19. Trading volume neared 8 million shares, data from StockAnalysis.com shows.
Funding remains a key concern for the setup. In a recent SEC filing, the company reported holding $12.7 million in cash as of Sept. 30, 2025, alongside a capital structure featuring over 17 million warrants outstanding.
But a pathway doesn’t equal approval. The study must still enroll sick hospital patients, steer clear of safety issues, and meet its endpoint. Any delay, disappointing results, or negative data would probably send the stock tumbling back down.
